ResMed (RMD) Q3 2026: Gross Margin Expands 290bps as Fabric Mask Adoption and Noctrix Deal Reshape Sleep Health Portfolio
ResMed delivered broad-based revenue and margin expansion in Q3, driven by operational discipline, new mask technologies, and sustained device growth across regions. The company’s tuck-in acquisition of Noctrix Health signals a deliberate push into adjacent sleep disorders, while robust cash flow and an active buyback program reinforce capital allocation flexibility. Management’s tone remains confident on long-term growth, even as component cost headwinds and payer dynamics demand vigilant execution.
Summary
- Fabric Mask Innovation Shifts Compliance Curve: Early data show fabric-based masks are driving higher patient adherence and market share gains.
- Noctrix Acquisition Expands Sleep Health Reach: Entry into restless leg syndrome adds a higher-growth, higher-margin lever to the portfolio.
- Margin Expansion Outpaces Cost Inflation: Operational leverage and supply chain optimization continue to offset emerging component and freight pressures.
Performance Analysis
ResMed posted double-digit headline revenue growth and widened gross margins by 290 basis points year over year, reflecting both product mix improvements and disciplined supply chain execution. Devices and masks each contributed, with masks and accessories up double digits globally, led by adoption of new fabric-based models such as AirTouch N30i and F30i Comfort. The Americas region saw masks and accessories revenue rise 14%, while Europe, Asia, and other regions sustained high single-digit growth across both devices and masks. Software revenue lifted 4%, with Medifox Dan offsetting softness in senior living and long-term care verticals.
Gross margin expansion was fueled by lower component costs, logistics efficiencies, and a shift to higher-value products, although management flagged early signs of component cost inflation and fuel-driven freight pressure. Operating expenses rose in line with topline growth, reflecting increased SG&A from Virtuox integration and stepped-up R&D for new product launches and tuck-in M&A. Cash flow conversion remained robust, enabling $262 million of capital returned to shareholders via dividends and accelerated buybacks.
- Mask Portfolio Drives Share Gain: AirTouch N30i and F30i launches are changing the basis of competition and lifting adherence rates.
- Device Segment Holds Leadership: US device sales grew 6%, with no material impact from recent competitor launches.
- Software and Data Ecosystem Expands: Virtuox and CME initiatives are deepening engagement with clinicians and patients, supporting funnel growth.
Overall, ResMed’s execution across multiple growth levers and disciplined cost management underpinned strong operating leverage, while investments in innovation and M&A set the stage for further portfolio expansion.
Executive Commentary
"ResMed continues to build the world's leading digital health ecosystem, encompassing sleep health, breathing health, and healthcare technology delivered in the home. Our gross margin expansion in the quarter was strong, 290 basis points year over year and 50 basis points of gross margin expansion sequentially. These results demonstrate the operational excellence that is a ResMed hallmark."
Mick Farrell, Chief Executive Officer
"Gross margin was 62.8% in the March quarter and increased by 290 basis points year over year and by 50 basis points sequentially. The increases were primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements."
Brett, Chief Financial Officer
Strategic Positioning
1. Fabric Mask Technology as a Differentiator
ResMed’s launch of fabric-based masks is reshaping patient adherence and competitive dynamics. The AirTouch N30i and F30i Comfort deliver a 6% higher 90-day compliance rate over silicone equivalents, a significant lever for lifetime value and recurring resupply revenue. Early adoption and positive feedback from both patients and providers suggest this innovation is expanding the addressable market and supporting premium price points.
2. Noctrix Health Acquisition: Adjacent Market Expansion
The acquisition of Noctrix Health for $340 million brings a higher-growth, higher-margin restless leg syndrome (RLS) device into ResMed’s Americas Devices segment. With RLS impacting 7% of adults globally, including 17 million in the US, this tuck-in is expected to leverage ResMed’s established HME and sleep physician channels. Management highlighted Noctrix’s faster top-line growth and superior gross margin profile, with plans to invest in SG&A and R&D to accelerate scaling and reimbursement coverage.
3. Digital Ecosystem and Clinical Education
ResMed is deepening its digital health ecosystem through Virtuox, CME programs, and local digital integration in markets like China. Its CME efforts have reached 45,000 unique clinicians, with 78% intending to alter clinical practice. These initiatives are increasing OSA screening and diagnosis, feeding the funnel for both devices and masks, while supporting market share gains and longer-term therapy adherence.
4. Capital Allocation and Shareholder Returns
Management is balancing internal investment with active capital return, deploying $262 million in Q3 through dividends and $175 million in share repurchases. The company plans to maintain at least this level of buybacks in Q4, while continuing to prioritize R&D and M&A for portfolio growth.
5. Margin Resilience Amid Supply Chain Volatility
Disciplined supply chain management and productivity initiatives are offsetting emerging cost headwinds, with management reiterating guidance for gross margin accretion through 2030. Platform standardization, vendor management, and logistics optimization are central to sustaining margin expansion, even as component cost inflation and fuel volatility rise.
Key Considerations
This quarter underscores ResMed’s ability to sustain growth and margin expansion through innovation, disciplined execution, and portfolio diversification. The company’s strategic bets on fabric mask technology and the Noctrix acquisition position it to address a broader spectrum of sleep and neurological disorders, while ongoing investments in digital health and clinical education should continue to drive funnel growth and adherence.
Key Considerations:
- Fabric Mask Adoption Accelerates: Compliance benefits and premium positioning are driving share gains and higher resupply rates.
- Noctrix Adds High-Margin Growth: Entry into RLS leverages existing channels and is expected to outpace core business growth rates.
- GLP-1 Tailwind Persists: Real-world data shows patients on both PAP and GLP-1 therapies are more likely to initiate and adhere to CPAP, supporting a multi-year demand opportunity.
- Operational Leverage Remains Strong: Margin expansion continues despite early signs of cost inflation, reflecting supply chain discipline and product mix improvements.
Risks
Component cost inflation and fuel-driven freight volatility present ongoing margin risks, even as operational initiatives have thus far offset these pressures. Payer reimbursement dynamics for new products, especially fabric masks and Noctrix’s RLS device, could impact adoption and profitability. Competitive launches remain a background risk, though management currently sees no major threat. Regulatory changes, especially global minimum tax impacts, may also pressure net income and EPS.
Forward Outlook
For Q4 2026, ResMed guided to:
- Gross margin of 62% to 63% for the full fiscal year
- SG&A as a percentage of revenue between 19% and 20%
- R&D as a percentage of revenue between 6% and 7%
- Net interest income of approximately $15 million
For full-year 2026, management maintained guidance:
- High single-digit revenue growth and earnings growth above revenue growth
- Effective tax rate between 21% and 23%
Management highlighted continued gross margin accretion, ongoing productivity initiatives, and robust free cash flow conversion as key drivers supporting both investment and capital return.
- Watch for scaling of Noctrix and integration into existing channels
- Continued expansion of fabric mask portfolio and digital ecosystem
Takeaways
ResMed’s Q3 results reinforce its leadership in sleep and respiratory health, with innovation and disciplined execution driving both top-line and margin expansion. The strategic push into RLS and continued investment in digital health and education position the company for sustained growth, even as cost and reimbursement headwinds persist.
- Portfolio Diversification Accelerates: The Noctrix acquisition and fabric mask innovation expand addressable markets and margin potential, supporting long-term growth.
- Margin Expansion Remains a Core Strength: Supply chain improvements and product mix are offsetting inflationary pressures, but vigilance is required as input costs rise.
- Future Watchpoints: Monitor reimbursement trends for new products, competitive responses to fabric mask technology, and the pace of GLP-1-driven demand funnel expansion.
Conclusion
ResMed’s Q3 performance demonstrates resilient growth and margin expansion, fueled by product innovation, disciplined operations, and strategic M&A. While cost and payer dynamics warrant close attention, the company’s expanding portfolio and digital ecosystem underpin a positive multi-year outlook.
Industry Read-Through
ResMed’s margin expansion and portfolio moves signal a broader shift in the medtech sector toward higher-value, recurring revenue models and adjacent disease state expansion. The success of fabric-based masks and the integration of digital health platforms highlight the importance of patient adherence and data-driven engagement. The acquisition of Noctrix underscores the value of tuck-in deals that leverage existing commercial infrastructure. Competitors in sleep, respiratory, and neurology should expect continued innovation pressure and rising patient expectations for comfort, connectivity, and outcomes. Payer and reimbursement dynamics remain a key industry watchpoint as new technologies challenge legacy pricing models.